Table 2. MVND and MPND analysis in glioma.
WHO II (n = 12) | WHO III (n = 12) | WHO IV (n = 16) | |
CD34+-MVND | 14.90±4.67 | 25.83±12.73a | 29.41±18.06a |
α-SMA+-MVND | 5.30±3.07 | 12.89±6.01a | 22.45±14.72ab |
α-SMA+/CD34+ MVND (%) | 35.57 | 49.90 | 76.36 |
MPND | 8.65±4.45 | 37.08±28.79a | 81.61±69.85ab |
a, P<0.01 vs grade II; b, P<0.01 vs grade III.
MVND, microvessel number/400 x field; MPND, α-SMA+ cell number in microvessel/400 x field.